News
Apogee’s pipeline in a product drug zumilokibart achieved significant disease clearance in a mid-stage atopic dermatitis trial, but investors were miffed by a royalty financing deal with Blackstone.
FEATURED STORIES
From Eli Lilly’s David Ricks to Pfizer’s Albert Bourla, the top five highest paid CEOs made a combined $157.8 million in 2025.
Partners Summit Therapeutics and Akeso are expected to steal the show at the American Society of Clinical Oncology’s annual conference with data from their potential Keytruda rival, alongside Revolution Medicine’s groundbreaking pancreatic cancer candidate and other assets that could reshape patient care.
The tragic tale of TIGIT is well known. However, RIPK1, myc, STING and alpha-synuclein have also left a trail of failed clinical trials, canceled partnerships and sunk investments in their wake.
FROM OUR EDITORS
Read our takes on the biggest stories happening in the industry.
The Department of Health and Human Services is spinning its wheels, unable to establish steady leadership at three major divisions—the CDC and the FDA’s two primary review units.
THE LATEST
Now that Omicron is becoming less common, its sister variant, BA.2, seems to be surging worldwide and in the U.S. For that and more, continue reading.
The companies that got money this week were the ones investing in ambitious, future-looking technologies, such as RNA genomics, biochips and antibody-drug conjugates.
The Media and Innovation Lab at the University of Miami is developing digital twins of patients in an effort to bring robust healthcare to underserved communities.
A checkpoint inhibitor under development by China’s Junshi Biosciences and Coherus BioSciences hit the mark in a Phase III lung cancer study.
Tokyo-based Eisai Inc. and Biogen announced modifications to their existing collaboration on developing the drug Aduhelm (aducanumab).
AnaptysBio announced that its drug candidate imsidolimab did not demonstrate efficacy in Phase II clinical trials in the treatment of moderate-to-severe acne.
Imugene announced a clinical trial collaboration and supply deal with Merck, while Merck said it is halting a Keytruda combination trial with AstraZeneca in prostate cancer.
After the announcement, Nektar shares dropped 36%, going from $6.47 per share to $4.16.
Sanofi secured a €300 million investment to advance the development of a subcutaneous formulation of Sarclisa, an anti-CD38 antibody for patients with multiple myeloma.
Araclon Biotech of Spain revealed positive data from the first part of a phase II trial for its immunotherapeutic vaccine to prevent Alzheimer’s disease- ABvac40.